Asset Acquisitions and Contingent Consideration (Details) - USD ($) $ in Millions			1 Months Ended		3 Months Ended		6 Months Ended
	Nov. 06, 2025	Oct. 31, 2024	Jul. 31, 2026	Jul. 31, 2025	Jun. 30, 2026	Dec. 31, 2025	Jun. 30, 2026
ICT License Acquisition
Asset Acquisition [Line Items]
Prepaid clinical supply					$ 3.5	$ 7.5	$ 3.5
Increase in prepaid clinical supply					$ 2.3		$ 4.0
Asset acquisition, contingent consideration, milestone achieved, shares to be issued					1,100,000
Asset acquisition, contingent consideration probable achievement, share-based compensation expense						$ 19.7
ICT License Acquisition | Subsequent Event
Asset Acquisition [Line Items]
Asset acquisition, contingent consideration, milestone achieved, shares issued			1,100,000
ImmPACT Bio USA Inc.
Asset Acquisition [Line Items]
Asset acquisition, upfront payment		$ 30.0
Cash acquired from acquisition		$ 11.9
Stock issuable, shares, acquisitions (in shares)		1,875,000
Contingent consideration, shares issued (in shares)				625,000
Equity issued for contingent consideration				$ 5.9
Innovative Cellular Therapeutics Holdings Limited and Innovative Cellular Therapeutics, Inc | ICT License Acquisition
Asset Acquisition [Line Items]
Prepaid clinical supply cap	$ 10.0
Asset acquisition, upfront cash payment	$ 40.0
Asset acquisition, share issuance (in shares)	1,900,000
Asset acquisition, clinical milestone, contingent cash payment	$ 30.0
Asset acquisition, late-stage regulatory milestone, maximum contingent cash payment	115.0
Asset acquisition, commercial sales milestones, maximum contingent cash payment	$ 675.0
Asset acquisition, clinical and regulatory milestones, maximum contingent share issuance	1,850,000
Asset acquisition, tiered royalties, annual net sales, maximum percentage	10.00%